A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to analyze the PK/PD of AvyCaz in critically ill patients in the
Intensive Care Unit (12). This study will include medical and post-surgical patients who
develop an infection where Avycaz can be utilized. Since these patients will have variable PK
parameters, the investigators will also analyze (time-kill) these serum concentrations (ex
vivo) against relevant clinical isolates (e.g. GNR with ESBL or KPC) from the ICU to
determine microbiologic activity of Avycaz in critically ill patients with variable
characteristics. Monte-Carlo simulations will also be conducted against clinical ICU isolates
(JMI labs) to help determine appropriate dosing schedules based upon these PK parameters.
Phase:
Phase 1
Details
Lead Sponsor:
Michigan State University
Treatments:
Avibactam Avibactam, ceftazidime drug combination Ceftazidime